🗞️ Published in Clinical Cancer Research, a VHIO-led study shows the preclinical promise of systemic targeted therapy in pseudomyxoma peritonei.
👨🔬 “Results of this proof-of-concept study represent an important first step toward developing and applying systemic targeted therapy in the clinic for patients who could for the first time derive benefit from personalized, molecularly matched treatments" says Hector G Palmer, senior author of this present study.
💬 “We have generated the world’s largest collection of patient-derived organoids and xenografts from patients with pseudomyxoma peritonei and showed that they are robust preclinical models to study this disease. To do so, we processed a total of 120 samples from 50 patients,”observes Jordi Martínez-Quintanilla Martínez, Senior Investigator of Palmer’s group and co-first author of this study along with Débora Cabot Romero, PhD, a Laboratory Technician of the same group.
🤝 This work was supported by the PMPnet #AcceleratorAward on Appendiceal Mucinous Neoplasms and Pseudomyxoma Peritonei: building a European multicentric cohort to accelerate new therapeutic perspectives, funded by the Asociación Española Contra el Cáncer, Cancer Research UK (CRUK) and AIRC - The Italian Foundation for Cancer Research ETS, and by CIBERONC/Instituto de Salud Carlos III.
➡️ https://lnkd.in/dXBvTRXd
Hospital Sant Joan Despi Moisés Broggi | ICERCA - Centres de Recerca de Catalunya | #VHIO #CancerResearch #Oncology #ClinicalCancerResearch #VHIOResearchers
We are delighted to inform you that your post has been successfully published on Oncodaily. Thank you for sharing such valuable content. https://oncodaily.com/insight/102203.html